Tumours of familial origin in the head and neck

Oral Oncology

Volumn 42, Issue 10, 2006, Pages 965-978

  Suárez, Carlos ^a,b   Rodrigo, Juan Pablo ^a,b   Ferlito, Alfio ^c   Cabanillas, Rubén ^a,b   Shaha, Ashok R ^d   Rinaldo, Alessandra ^c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c UNIVERSITY OF UDINE   (Italy)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Familial carcinoma; Head and neck; Multiple endocrine neoplasias; Neurofibromatosis; Paraganglioma

Indexed keywords

IMATINIB; PROTON PUMP INHIBITOR;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARNEY COMPLEX; CLINICAL FEATURE; ENDOCRINE TUMOR; FAMILIAL CANCER; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENOTYPE; HEAD AND NECK TUMOR; HUMAN; HYPERPARATHYROIDISM; MEN 1 GENE; MEN 2 GENE; MORBIDITY; MORTALITY; MULTIPLE ENDOCRINE NEOPLASIA; NASOPHARYNX CARCINOMA; NEUROFIBROMATOSIS; NONHUMAN; PARAGANGLIOMA; PARATHYROID TUMOR; PATIENT CARE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; SDHB GENE; SDHC GENE; SDHD GENE; SIPPLE SYNDROME; SQUAMOUS CELL CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; NASOPHARYNGEAL NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; NEUROFIBROMATOSES; PARAGANGLIOMA;

EID: 33750034550     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2006.03.002     Document Type: Review

References (121)

1. Knudson A.G. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 122 (1996) 135-140
2. Pellitteri P.K., Rinaldo A., Myssiorek D., Jackson C.G., Bradley P.J., Devaney K.O., et al. Paragangliomas of the head and neck. Oral Oncol 40 (2004) 563-575
3. Drovdlic C.M., Myers E.N., Peters J.A., Baysal B.E., Brackmann D.E., Slattery III W.H., et al. Proportion of heritable paraganglioma cases and associated clinical characteristics. Laryngoscope 111 (2001) 1822-1827
4. Bikhazi P.H., Roeder E., Attaie A., and Lalwani A.K. Familial paragangliomas: the emerging impact of molecular genetics on evaluation and management. Am J Otol 20 (1999) 639-643
5. Manolidis S., Shohet J.A., Jackson C.G., and Glasscock III M.E. Malignant glomus tumors. Laryngoscope 109 (1999) 30-34
6. Hayes W.S., Davidson A.J., Grimley P.M., and Hartman D.S. Extraadrenal retroperitoneal paraganglioma: clinical, pathologic, and CT findings. AJR Am J Roentgenol 155 (1990) 1247-1250
7. Sclafani L.M., Woodruff J.M., and Brennan M.F. Extraadrenal retroperitoneal parangliomas: natural history and response to treatment. Surgery 108 (1990) 1124-1129 discussion 1129-30
8. Rinaldo A., Ferlito A., Myssiorek D., and Devaney K.O. Which paragangliomas of the head and neck have a higher rate of malignancy?. Oral Oncol 40 (2004) 458-460
9. Myssiorek D., Rinaldo A., Barnes L., and Ferlito A. Laryngeal paraganglioma: an updated critical review. Acta Otolaryngol 124 (2004) 995-999
10. Ferlito A, Devaney KO, Rinaldo A. Neuroendocrine neoplasms of the larynx: advances in identification, understanding and management. Oral Oncol, in press. doi:10.1016/j.oraloncology.2006.01.002.
11. Jansen J.C., van den Berg R., Kuiper A., van der Mey A.G., Zwinderman A.H., and Cornelisse C.J. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 88 (2000) 2811-2816
12. Boedeker C.C., Ridder G.J., and Schipper J. Paragangliomas of the head and neck: diagnosis and treatment. Fam Cancer 4 (2005) 55-59
13. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
14. Carney J.A., Sheps S.G., Go V.L., and Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 296 (1977) 1517-1518
15. Carney J.A. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney's triad): Natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74 (1999) 543-552
16. Perry C.G., Young Jr. W.F., McWhinney S.R., Bei T., Stergiopoulos S., Knudson R.A., et al. Functioning paraganglioma and gastrointestinal stromal tumor of the jejunum in three women: syndrome or coincidence. Am J Surg Pathol 30 (2006) 42-49
17. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287 (2000) 848-851
18. Astuti D., Latif F., Dallol A., Dahia P.L., Douglas F., George E., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69 (2001) 49-54
19. Niemann S., and Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26 (2000) 268-270
20. Baysal B.E., Willett-Brozick J.E., Lawrence E.C., Drovdlic C.M., Savul S.A., McLeod D.R., et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39 (2002) 178-183
21. Astrom K., Cohen J.E., Willett-Brozick J.E., Aston C.E., and Baysal B.E. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum Genet 113 (2003) 228-237
22. Neumann H.P., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R., Muresan M., et al. European-American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292 (2004) 943-951
23. Baysal B.E. Hereditary paraganglioma targets diverse paraganglia. J Med Genet 39 (2002) 617-622
24. Vanharanta S., Buchta M., McWhinney S.R., Virta S.K., Peczkowska M., Morrison C.D., et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 74 (2004) 153-159
25. Pawlu C., Bausch B., and Neumann H.P. Mutations of the SDHB, and SDHD genes. Fam Cancer 4 (2005) 49-54
26. Renard L., Godfraind C., Boon L.M., and Vikkula M. A novel mutation in the SDHD gene in a family with inherited paragangliomas-implications of genetic diagnosis for follow up and treatment. Head Neck 25 (2003) 146-151
27. Erickson D., Kudva Y.C., Ebersold M.J., Thompson G.B., Grant C.S., van Heerden J.A., et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 86 (2001) 5210-5216
28. Rubin A.D., Cheng S.S., and Bradford C.R. Laryngeal paraganglioma in a patient with multiple head and neck paragangliomas. Otolaryngol Head Neck Surg 132 (2005) 520-522
29. Isik A.C., Erem C., Imamoglu M., Cinel A., Sari A., and Maral G. Familial paraganglioma. Eur Arch Otorhinolaryngol 263 (2006) 23-31
30. Hoegerle S., Ghanem N., Altehoefer C., Schipper J., Brink I., Moser E., et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30 (2003) 689-694
31. Telischi F.F., Bustillo A., Whiteman M.L., Serafini A.N., Reisberg M.J., Gomez-Marin O., et al. Octreotide scintigraphy for the detection of paragangliomas. Otolaryngol Head Neck Surg 122 (2000) 358-362
32. Bustillo A., Telischi F., Weed D., Civantos F., Angeli S., Serafini A., et al. Octreotide scintigraphy in the head and neck. Laryngoscope 114 (2004) 434-440
33. Myssiorek D., and Palestro C.J. 111Indium pentetreotide scan detection of familial paragangliomas. Laryngoscope 108 (1998) 228-231
34. Le Rest C., Bomanji J.B., Costa D.C., Townsend C.E., Visvikis D., and Ell P.J. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 28 (2001) 478-482
35. Gujrathi C.S., and Donald P.J. Current trends in the diagnosis and management of head and neck paragangliomas. Curr Opin Otolaryngol Head Neck Surg 13 (2005) 339-342
36. Doherty G.M., Lairmore T.C., and DeBenedetti M.K. Multiple endocrine neoplasia type 1 parathyroid adenoma development over time. World J Surg 28 (2004) 1139-1142
37. Sato M., Miyauchi A., and Takahara J. Clinical aspects of hyperparathyroidism in Japanese multiple endocrine neoplasia type 1. Biomed Pharmacother 54 Suppl 1 (2000) 86s-89s
38. Gibril F., Venzon D.J., Ojeaburu J.V., Bashir S., and Jensen R.T. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86 (2001) 5282-5293
39. Grant C.S. Insulinoma. Best Pract Res Clin Gastroenterol 19 (2005) 783-798
40. Verges B., Boureille F., Goudet P., Murat A., Beckers A., Sassolas G., et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87 (2002) 457-465
41. Teh B.T., Zedenius J., Kytola S., Skogseid B., Trotter J., Choplin H., et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 228 (1998) 99-105
42. Guo S.S., and Sawicki M.P. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol 15 (2001) 1653-1664
43. Ellard S., Hattersley A.T., Brewer C.M., and Vaidya B. Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf) 62 (2005) 169-175
44. Bartsch D.K., Langer P., Wild A., Schilling T., Celik I., Rothmund M., et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?. Surgery 128 (2000) 958-966
45. Marx S.J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5 (2005) 367-375
46. Arnalsteen L.C., Alesina P.F., Quiereux J.L., Farrel S.G., Patton F.N., Carnaille B.M., et al. Long-term results of less than total parathyroidectomy for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 132 (2002) 1119-1124
47. Hellman P., Skogseid B., Oberg K., Juhlin C., Akerstrom G., and Rastad J. Primary and reoperative parathyroid operations in hyperparathyroidism multiple endocrine neoplasia type 1. Surgery 124 (1998) 993-999
48. Nikou G.C., Toubanakis C., Nikolaou P., Giannatou E., Marinou K., Safioleas M., et al. Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology 52 (2005) 1668-1676
49. Lee N.C., and Norton J.A. Multiple endocrine neoplasia type 2B-genetic basis and clinical expression. Surg Oncol 9 (2000) 111-118
50. Kouvaraki M.A., Shapiro S.E., Perrier N.D., Cote G.J., Gagel R.F., Hoff A.O., et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 (2005) 531-544
51. Cohen M.S., Phay J.E., Albinson C., DeBenedetti M.K., Skinner M.A., Lairmore T.C., et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 235 (2002) 648-654
52. Yip L., Cote G.J., Shapiro S.E., Ayers G.D., Herzog C.E., Sellin R.V., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138 (2003) 409-416
53. Schuffenecker I., Virally-Monod M., Brohet R., Goldgar D., Conte-Devolx B., Leclerc L., et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe d'Etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab 83 (1998) 487-491
54. Szinnai G., Meier C., Komminoth P., and Zumsteg U.W. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 111 (2003) E132-E139
55. Skinner M.A., Moley J.A., Dilley W.G., Owzar K., Debenedetti M.K., and Wells Jr. S.A. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353 (2005) 1105-1113
56. O'Riordain D.S., O'Brien T., Grant C.S., Weaver A., Gharib H., and van Heerden J.A. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 114 (1993) 1031-1037
57. Herfarth K.K., Bartsch D., Doherty G.M., Wells Jr. S.A., and Lairmore T.C. Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 120 (1996) 966-974
58. Dwight T., Twigg S., Delbridge L., Wong F.K., Farnebo F., Richardson A.L., et al. Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13. Clin Endocrinol (Oxf) 53 (2000) 85-92
59. Villablanca A., Wassif W.S., Smith T., Hoog A., Vierimaa O., Kassem M., et al. Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. Eur J Endocrinol 147 (2002) 313-322
60. DeLellis R.A. Parathyroid carcinoma: an overview. Adv Anat Pathol 12 (2005) 53-61
61. Lee S., Hong S.W., Shin S.J., Kim Y.M., Rhee Y., Jeon B.I., et al. Papillary thyroid carcinoma associated with familial adenomatous polyposis: molecular analysis of pathogenesis in a family and review of the literature. Endocr J 51 (2004) 317-323
62. Rohaizak M., Jasmi A.Y., Ismail M.A., Munchar M.J., and Meah F.A. Thyroid carcinoma in patients with familial adenomatous polyposis. Asian J Surg 26 (2003) 183-185
63. Tsilchorozidou T., Vafiadou E., Yovos J.G., Romeo G., McKay J., Lesueur F., et al. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci. Thyroid 15 (2005) 1349-1354
64. Hemminki K., Eng C., and Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 90 (2005) 5747-5753
65. Matyakhina L., Pack S., Kirschner L.S., Pak E., Mannan P., Jaikumar J., et al. Chromosome 2 (2p16) abnormalities in Carney complex tumours. J Med Genet 40 (2003) 268-277
66. Stratakis C.A. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit (PRKAR1A) in patients with the complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas" (Carney complex). Ann N Y Acad Sci 968 (2002) 3-21
67. Riccardi M. Neurofibromatosis: past, present and future. N Engl J Med 324 (1991) 1283-1285
68. Reynolds R.M., Browning G.G.P., Nawroz I., and Campbell I.W. Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet 361 (2003) 1552-1554
69. Viskochil D., Buchberg A.M., Xu G., Cawthon R.M., Stevens J., Wolff R.K., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62 (1990) 187-192
70. Cawthon R.M., Weiss M., Xu G., Viskochil D., Culver M., Stevens J., et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure and point mutations. Cell 62 (1990) 193-201
71. Ballester R., Marchuk D.A., Boguski M., Saulino A.M., Letcher R., Wigler M., et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63 (1990) 851-859
72. Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., Haubruck H., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63 (1990) 843-849
73. Lau N., Feldkamp M.M., Roncari L., Loehr A.H., Shannon P., Gutmann D.H., et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 59 (2000) 759-767
74. Sherman L.S., Atit R., Rosenbaum T., Cox A.D., and Ratner N. Single cell Ras-GTP analysis reveals altered ras activity in a single population of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 275 (2000) 30740-30745
75. Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., and Downward J. Aberrant regulation of ras proteins in tumour cells from type 1 neurofibromatosis patients. Nature 356 (1992) 713-715
76. Menon A.G., Anderson K.M., Riccardi V.M., Chung R.Y., Whaley J.M., Yandell D.W., et al. Chromosome 17p deletions and p53 gene mutation associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 87 (1990) 5435-5439
77. Vogel K.S., Kleese L.J., Velasco-Miguel S., Meyers K., Rushing E.J., and Parada L.F. Mouse tumor model for neurofibromatosis type 1. Science 286 (1999) 2176-2179
78. The I., Hannigan G.E., Cowley G.S., Reginald S., Zhong Y., Gusella J.F., et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276 (1997) 791-794
79. Geist R.T., and Gutmann D.H. Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neurosci Lett 211 (1996) 85-88
80. Evans D.G.R., Huson S.M., Donnai D., Neary W., Blair V., Newton V., et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet 29 (1992) 841-846
81. MacCollin M., and Mautner V.-.F. The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 5 (1998) 243-252
82. Gijtenbeek J.M., Gabreels-Festen A.A., Lammens M., Zwarts M.J., and van Engelen B.G. Mononeuropathy multiplex as the initial manifestation of neurofibromatosis type 2. Neurology 56 (2001) 1766-1768
83. Evans D.G.R., Huson S.M., Donnai D., Neary W., Blair V., Newton V., et al. A clinical study of type 2 neurofibromatosis. Q J Med 84 (1992) 603-618
84. Gutmann D.H., Aylsworth A., Carey J.C., Korf B., Marks J., Pyeritz R.E., et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278 (1997) 51-57
85. Baser M.E., Friedman J.M., Wallace A.J., Ramsden R.T., Joe H., and Evans D.G. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59 (2002) 1759-1765
86. Trofatter J.A., MacCollin M.M., Rutter J.L., Murrell J.R., Duyao M.P., Parry D.M., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72 (1993) 791-800
87. Rouleau G.A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363 (1993) 515-521
88. Kang B.S., Cooper D.R., Devedjiev Y., Derewenda U., and Derewenda Z.S. The structure of the FERM domain of merlin, the neurofibromatosis type 2 gene product. Acta Crystallogr D Biol Crystallogr 58 (2002) 381-391
89. Giovannini M., Robanus-Maandag E., Niwa-Kawakita M., van der Valk M., Woodruff J.M., Goutebroze L., et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 13 (1999) 978-986
90. Morrison H., Sherman L.S., Legg J., Banine F., Isacke C., Haipek C.A., et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15 (2001) 968-980
91. Fernandez-Valle C., Tang Y., Ricard J., Rodenas-Ruano A., Taylor A., Hackler E., et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 31 (2002) 354-362
92. Gutmann D.H., Haipek C.A., Burke S.P., Sun C.X., Scoles D.R., and Pulst S.M. The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the "open" conformation and suppresses cell growth and motility. Hum Mol Genet 10 (2001) 825-834
93. Ruttledge M.H., Sarrazin J., Rangaratnam S., Phelan C.M., Twist E., Merel P., et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6 (1994) 180-184
94. Merel P., Hoang-Xuan K., Sanson M., Moreau-Aubry A., Bijlsma E.K., Lazaro C., et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13 (1995) 211-216
95. Kluwe L., MacCollin M., Tatagiba M., Thomas S., Hazim W., Haase W., et al. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet 77 (1998) 228-233
96. Baser M.E., Makariou E.V., and Parry D.M. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2. J Neurosurg 96 (2002) 217-222
97. Baser M.E., Ragge N.K., Riccardi V.M., Janus T., Gantz B., and Pulst S.M. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am J Med Genet 64 (1996) 563-567
98. Zhao Y., Kumar R.A., Baser M.E., Evans D.G., Wallace A., Kluwe L., et al. Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2). Genet Epidemiol 23 (2002) 245-259
99. Chan A.T.C., Leo P.M.L., and Johnson P.J. Nasopharyngeal carcinoma. Ann Oncol 13 (2002) 1007-1015
100. Jia W.H., Feng B.J., Xu Z.L., Zhang X.S., Huang P., Huang L.X., et al. Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer 101 (2004) 363-369
101. Zeng Y.X., and Jia W.H. Familial nasopharyngeal carcinoma. Semin Cancer Biol 12 (2002) 443-450
102. Levine P.H., Pocinki A.G., Madigan P., and Bale S. Familial nasopharyngeal carcinoma in patients who are not Chinese. Cancer 70 (1992) 1024-1029
103. Friborg J., Wohlfahrt J., Koch A., Storm H., Olsen O.R., and Melbye M. Cancer susceptibility in nasopharyngeal carcinoma families-a population-based cohort study. Cancer Res 65 (2005) 8567-8572
104. Ng W.T., Yau T.K., Yung R.W., Sze W.M., Tsang A.H., Law A.L., et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 113 (2005) 998-1001
105. Xiong W., Zeng Z.Y., Xia J.H., Xia K., Shen S.R., Li X.L., et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 64 (2004) 1972-1974
106. Deng L., Jing N., Tan G., Zhou M., Zhan F., Xie Y., et al. A common region of allelic loss on chromosome region 3p25.3-26.3 in nasopharyngeal carcinoma. Genes Chromosomes Cancer 23 (1998) 21-25
107. Lo K.W., Teo P.M., Hui A.B., To K.F., Tsang Y.S., Chan S.Y., et al. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 60 (2000) 3348-3353
108. Chan A.S., To K.F., Lo K.W., Mak K.F., Pak W., Chiu B., et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 60 (2000) 5365-5370
109. Feng B.J., Huang W., Shugart Y.Y., Lee M.K., Zhang F., Xia J.C., et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 31 (2002) 395-399
110. Jemal A., Thomas A., Murray A., and Thun M. Cancer statistics 2002. CA Cancer J Clin 52 (2002) 23-47
111. Ankathil R., Mathew A., Joseph F., and Nair M.K. Is oral cancer susceptibility inherited? Report of five oral cancer families. Eur J Cancer B Oral Oncol 32B (1996) 63-67
112. Copper M.P., Jovanovic A., Nauta J.J., Braakhuis B.J., de Vries N., van der Waal I., et al. Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 121 (1995) 157-160
113. Gonzalez M.V., Alvarez V., Pello M.F., Menéndez M.J., Suárez C., and Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 51 (1998) 294-298
114. Yarbrough W.G., Aprelikova O., Pei H., Olshan A.F., and Liu E.T. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst 88 (1996) 1489-1491
115. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 (1994) 436-440
116. Kamb A., Shattuck-Eidens D., Eeles R., Liu Q., Gruis N.A., Ding W., et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8 (1994) 23-26
117. Whelan A.J., Bartsch D., and Goodfellow P.J. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333 (1995) 975-977
118. Okami K., Reed A.L., Cairns P., Koch W.M., Westra W.H., Wehage S., et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 18 (1999) 3541-3545
119. Shahnavaz S.A., Bradley G., Regezi J.A., Thakker N., Gao L., Hogg D., et al. Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas. Cancer Res 61 (2001) 2371-2375
120. Reed A.L., Califano J., Cairns P., Westra W.H., Jones R.M., Koch W., et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56 (1996) 3630-3633
121. Yu K.K., Zanation A.M., Moss J.R., and Yarbrough W.G. Familial head and neck cancer: molecular analysis of a new clinical entity. Laryngoscope 112 (2002) 1587-1593